Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shares are trading higher after the company announced positive topline results from an ongoing Phase 2a study of TEV ‘408. The study met its primary endpoint.
- Teva stock is trading at elevated levels. Where are TEVA shares going?
TEV ‘408 Shows Promise in Celiac Disease
TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo in adults with celiac disease. The study’s primary endpoint measured the villous height-to-crypt depth ratio, showing least squares mean change from baseline of -0.43 for TEV ‘408 compared with -0.88 for placebo. The drug also showed a favorable effect on intestinal inflammation and demonstrated lower gastrointestinal symptom scores versus placebo. TEV ‘408 was well-tolerated, with no safety signals observed to date.
“A strict gluten-free diet has long been the only option for people living with celiac disease. Yet, even with strict adherence to a gluten-free diet, many continue to experience symptoms, intestinal damage and a significant impact on their daily lives,” said Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “These results underscore the potential to move beyond managing gluten exposure and address celiac disease at its biological source.”
TEV ‘408 Advances with Vitiligo Study and Strategic Funding
TEV ‘408 is also being evaluated as a treatment for vitiligo, with Teva advancing the drug into a Phase 2b study in that indication following encouraging Phase 1b results. Teva entered a strategic funding agreement with Royalty Pharma in January 2026, under which Teva is eligible to receive up to $500 million to accelerate the clinical development of TEV ‘408.
Teva Shares Edge Higher
TEVA Price Action: At the time of publication, Teva shares are trading 2.74% higher at $37.18, according to data from Benzinga Pro.
Image via Shutterstock
Login to comment